Vaxcyte (PCVX) said Wednesday its ongoing phase 2 study assessing VAX-31 for the prevention of invasive pneumococcal disease in infants is advancing to its second and final stage.
The company said participants who received VAX-31 in the first stage will continue the standard dosing regimen as part of the second stage.
Vaxcyte said it expects to release topline data from the study's primary three-dose immunization series in the middle of next year, followed by topline data from the booster dose about nine months later.
In infants, the VAX-31 was designed to cover about 94% of invasive pneumococcal disease and roughly 93% of acute otitis media caused by streptococcus pneumoniae in children under five years old in the United States.
Shares of Vaxcyte were up nearly 3% in recent trading.
Price: 88.88, Change: +2.37, Percent Change: +2.73
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。